High quality Drug Metabolism and Pharmacokinetics (DMPK) studies are at the heart of a successful drug discovery project. Done right, they can have a substantial impact on the development timeline, total cost of the project, and quality of the molecules that progress to the clinic.

At Sygnature Discovery we have built a DMPK drug discovery team with a wealth of experience. This enables us to do more than just deliver accurate data: we provide expert analysis and interpretation of the results. This is a key feature in helping drive your project forward.

We offer an extensive range of validated in silico, in vitro and in vivo DMPK services for drug discovery, backed up by a comprehensive portfolio of analytical techniques. We can design flexible DMPK screening cascades to support medicinal chemistry programmes, including bespoke method development.

Working closely with Chemistry and Bioscience, our approach is one of collaboration, partnering with clients to develop a greater understanding of the target and the properties that a successful drug should have. Expert guidance and problem-solving suggestions from our experienced team will help you optimise potential drug molecules, increasing the likelihood of success.

Drug Metabolism and Pharmacokinetics (DMPK) Services:

DMPK Services

DMPK Consultancy

Sygnature Discovery offers a range of DMPK consultancy services to drug discovery research teams within the academic, pharmaceutical, biotechnology, charity and CRO sectors as well as to life science venture capital funds.


Physicochemical Properties of Drugs

It is well understood that poor physicochemical properties are associated with increased failure of drug candidates within the pre-clinical and clinical development process. Assessing these parameters during the discovery optimisation process is critical.


In Silico and PBPK Modelling

Sygnature In Silico Modelling uses the GastroPlusTM software package that simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes including oral, intravenous, inhaled, ocular and dermal. This enables data integration within the context of a virtual animal or human model.


In Vitro ADME Pharmacology

The assessment of the Absorption, Distribution, Metabolism, and Excretion (ADME Pharmacology) properties of compounds is a critical component is supporting the development of compounds within Discovery and Development. 


In Vivo Pharmacokinetics (PK)

At Sygnature Discovery we offer services to support your non-GLP in vivo Pharmacokinetics studies in preclinical species including the planning of these studies and the analysis of any samples generated by UPLC-MS



Sygnature’s state-of-the-art non-GLP bioanalysis service brings together the latest instrumentation and technology, which, combined with the wealth of experience across the team, is used to provide quantitative measures of metabolites for the purpose of pharmacokinetics, toxicokinetics, bioequivalence and exposure-response studies.


Metabolite Drug Identification (Met-ID)

Sygnature’s DMPK and biotransformational capabilities are supplemented by extensive expertise in complementary analytical techniques, including high-resolution mass spectrometry, nuclear magnetic resonance, chemically intelligent software algorithms and mass spectrometry imaging.


Latest News

View All

Leading UK Drug Discovery CROs Unite as…

Sygnature Discovery Announces Expansion at Alderley Park

Understanding & Predicting Brain Penetration for CNS-targeted…